Glaukos Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas William Burns
- Full Time Employees
- 1,094
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- One Glaukos Way Aliso Viejo CA United States 92656
- IPO Date
- Jun 24, 2015
- CIK
- 0001192448
- Website
- glaukos.com
- Similar Companies
- Business
- Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Founded in 1998 and headquartered in Aliso Viejo, California, Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) technology, launching the first MIGS device commercially in 2012. Its core products include the iStent family of micro-scale surgical devices to reduce intraocular pressure in glaucoma patients; the iDose TR, a first-of-its-kind, long-duration intracameral procedural pharmaceutical implant delivering continuous glaucoma drug therapy inside the eye; a proprietary, FDA-approved corneal cross-linking therapy for keratoconus; transdermal pharmaceuticals for treating glaucoma, dry eye, presbyopia, and ocular surface diseases; and bio-erodible sustained-release drug delivery implants for retinal diseases. The company operates globally with locations in the United States, Canada, the United Kingdom, Germany, Japan, Australia, and Brazil. Recent major developments include the commercial launch of the iDose TR implant in 2024, which delivers sustained glaucoma drug therapy, marking a significant advancement in dropless therapies. In 2025, Glaukos reported record net sales with notable growth in glaucoma product sales, raised full-year 2025 revenue guidance to $490 million to $495 million, and issued preliminary 2026 sales guidance of $600 million to $620 million. The company also received FDA approval for a new eye therapy named Epioxa, expected to be commercially available in early 2026. Glaukos continues to invest in expanding its pipeline of novel dropless platform technologies aimed at improving patient outcomes and advancing the standard of care across its ophthalmic focus areas. It maintains a strong financial position with no debt and substantial cash reserves as of the third quarter of 2025. Glaukos' shares trade on the New York Stock Exchange under the ticker symbol GKOS.
Company News
Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction
Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings
Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket
Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript
Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates
Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics
Glaukos Q3 Earnings Call Highlights
Glaukos Announces Third Quarter 2026 Financial Results
State of Alaska Department of Revenue Sells 9,393 Shares of Glaukos Corporation $GKOS
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
Glaukos: The Second J-Code Rewrites The Risk Math
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Glaukos says late-stage eye disease treatment shows lasting benefits after single dose
Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus
Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28